136 related articles for article (PubMed ID: 2168839)
1. 3'-Azido-3'-deoxythymidine ameliorates the thrombocytopenia observed in a murine model of AIDS.
Chow FP; Sutton PA; Hamburger AW
Exp Hematol; 1990 Oct; 18(9):1038-41. PubMed ID: 2168839
[TBL] [Abstract][Full Text] [Related]
2. Effects of in vivo administration of stem cell factor on thrombopoiesis in normal and immunodeficient mice.
Chow FP; Zsebo K; Hamburger AW
Exp Hematol; 1993 Aug; 21(9):1255-62. PubMed ID: 7687220
[TBL] [Abstract][Full Text] [Related]
3. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent changes induced by azidothymidine in erythroid progenitor colonies in immunodeficient mice.
Chow FP; Hamburger AW
Exp Hematol; 1992 Feb; 20(2):245-50. PubMed ID: 1544395
[TBL] [Abstract][Full Text] [Related]
5. Acute toxic effects of 3'-azido-3'-deoxythymidine (AZT) on normal and regenerating murine hematopoiesis.
Scheding S; Media JE; Nakeff A
Exp Hematol; 1994 Jan; 22(1):60-5. PubMed ID: 8282060
[TBL] [Abstract][Full Text] [Related]
6. In vivo toxicity of 3'-azido-3'-deoxythymidine (AZT) on CBA/Ca mice.
Cronkite EP; Bullis J
Int J Cell Cloning; 1990 Sep; 8(5):332-45. PubMed ID: 2230284
[TBL] [Abstract][Full Text] [Related]
7. In vivo tissue disposition of 3'-azido-3'-deoxythymidine and its anabolites in control and retrovirus-infected mice.
Chow HH; Li P; Brookshier G; Tang Y
Drug Metab Dispos; 1997 Apr; 25(4):412-22. PubMed ID: 9107539
[TBL] [Abstract][Full Text] [Related]
8. In vivo biodistribution, pharmacokinetic parameters, and brain uptake of 5-halo-y-methoxy(or ethoxy)-5,6-dihydro-3'-azido-3'-deoxythymidine diastereomers as potential prodrugs of 3'-azido-3'-deoxythymidine.
Wang L; Morin KW; Kumar R; Cheraghali M; Todd KG; Baker GB; Knaus EE; Wiebe LI
J Med Chem; 1996 Feb; 39(4):826-33. PubMed ID: 8632406
[TBL] [Abstract][Full Text] [Related]
9. Response of AIDS-related thrombocytopenia to intravenous and oral azidothymidine (3'-azido-3'-deoxythymidine).
Gottlieb MS; Wolfe PR; Chafey S
AIDS Res Hum Retroviruses; 1987; 3(2):109-14. PubMed ID: 3113461
[TBL] [Abstract][Full Text] [Related]
10. Long-term bone marrow stromal and hemopoietic toxicity to AZT: protective role of heme and IL-1.
Abraham NG; Chertkov JL; Staudinger R; Jiang S; Lutton JD; Argani I; Levere RD; Kappas A
Exp Hematol; 1993 Feb; 21(2):263-8. PubMed ID: 7678812
[TBL] [Abstract][Full Text] [Related]
11. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice.
Prakash O; Teng S; Ali M; Zhu X; Coleman R; Dabdoub RA; Chambers R; Aw TY; Flores SC; Joshi BH
Arch Biochem Biophys; 1997 Jul; 343(2):173-80. PubMed ID: 9224727
[TBL] [Abstract][Full Text] [Related]
12. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
[TBL] [Abstract][Full Text] [Related]
13. Lifetime treatment of mice with azidothymidine (AZT) produces myelodysplasia.
Inoue T; Cronkite EP; Hirabayashi Y; Bullis JE; Mitsui H; Umemura T
Leukemia; 1997 Apr; 11 Suppl 3():123-7. PubMed ID: 9209318
[TBL] [Abstract][Full Text] [Related]
14. Failure of stem cell factor to ameliorate AZT-induced anemia in immunodeficient mice.
Hamburger AW; Zsebo K; Chow FP
Eur J Haematol; 1993 Mar; 50(3):172-8. PubMed ID: 7682517
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of azidothymidine, 2'-3'-dideoxyadenosine, and 2'-3'-dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and from patients with AIDS.
Ganser A; Greher J; Völkers B; Staszewski S; Hoelzer D
Exp Hematol; 1989 May; 17(4):321-5. PubMed ID: 2540017
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients.
De Simone C; Ferrazzi M; Bitonti F; Falciano M; Tzantzoglou S; Delia S; Sorice F
Immunopharmacol Immunotoxicol; 1988; 10(4):437-41. PubMed ID: 2469710
[TBL] [Abstract][Full Text] [Related]
17. Catabolism of 3'-azido-3'-deoxythymidine in hepatocytes and liver microsomes, with evidence of formation of 3'-amino-3'-deoxythymidine, a highly toxic catabolite for human bone marrow cells.
Cretton EM; Xie MY; Bevan RJ; Goudgaon NM; Schinazi RF; Sommadossi JP
Mol Pharmacol; 1991 Feb; 39(2):258-66. PubMed ID: 1996084
[TBL] [Abstract][Full Text] [Related]
18. 3'-Azido-3'-deoxythymidine prevents induction of murine acquired immunodeficiency syndrome in C57BL/10 mice infected with LP-BM5 murine leukemia viruses, a possible animal model for antiretroviral drug screening.
Ohnota H; Okada Y; Ushijima H; Kitamura T; Komuro K; Mizuochi T
Antimicrob Agents Chemother; 1990 Apr; 34(4):605-9. PubMed ID: 1693056
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex (ARC): an open uncontrolled treatment study.
Stambuk D; Youle M; Hawkins D; Farthing C; Shanson D; Farmer R; Lawrence A; Gazzard B
Q J Med; 1989 Feb; 70(262):161-74. PubMed ID: 2512592
[TBL] [Abstract][Full Text] [Related]
20. Zidovudine toxicity to murine bone marrow may be affected by the exact frequency of drug administration.
Agur Z; Arnon R; Sandak B; Schechter B
Exp Hematol; 1991 Jun; 19(5):364-8. PubMed ID: 2026186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
